Loading...
We would love for you to become a part of our community. Join our Discord to connect with us and other members!
- Ticker
- ABEO
- Price
- 6.02
- Stock movement up
- +0.11 (1.86%)
- Company name
- Abeona Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 261.70M
- Ent value
- 320.79M
- Price/Sales
- 92.67
- Price/Book
- 5.72
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 16.28%
- 1 year return
- 4.70%
- 3 year return
- 165.96%
- 5 year return
- 12.98%
- 10 year return
- 5.57%
Last updated: 2025-01-03
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ABEO does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 92.67 |
| Price to Book | 5.72 |
| EV to Sales | 113.59 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 43.47M |
| EPS (TTM) | -1.48 |
| FCF per share (TTM) | -1.05 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.82M |
| Gross profit (TTM) | -288.00K |
| Operating income (TTM) | -60.75M |
| Net income (TTM) | -71.03M |
| EPS (TTM) | -1.48 |
| EPS (1y forward) | -1.13 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -10.20% |
| Operating margin (TTM) | -2151.13% |
| Profit margin (TTM) | -2515.30% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 15.73M |
| Net receivables | 1.61M |
| Total current assets | 112.66M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 22.29M |
| Total assets | 120.59M |
| Accounts payable | 2.79M |
| Short/Current long term debt | 23.11M |
| Total current liabilities | 18.42M |
| Total liabilities | 74.82M |
| Shareholder's equity | 45.77M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -48.69M |
| Capital expenditures (TTM) | 1.88M |
| Free cash flow (TTM) | -50.57M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -155.18% |
| Return on Assets | -58.90% |
| Return on Invested Capital | -106.76% |
| Cash Return on Invested Capital | -76.00% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.91 |
| Daily high | 6.07 |
| Daily low | 5.86 |
| Daily Volume | 293K |
| All-time high | 47188.00 |
| 1y analyst estimate | 16.75 |
| Beta | 1.50 |
| EPS (TTM) | -1.48 |
| Dividend per share | - |
| Ex-div date | 22 Jul 2022 |
| Next earnings date | 17 Mar 2025 |
Downside potential
Loading...
Downside potential data
| ABEO | S&P500 | |
| Current price drop from All-time high | -99.99% | -2.61% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 17 Jun 2022 | 9 Mar 2009 |
| Avg drop from high | -92.48% | -11.12% |
| Avg time to new high | 428 days | 12 days |
| Max time to new high | 8049 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
261.70M
Marketcap category
Small-cap
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Employees
84
Investor relations
-
SEC filings
CEO
Joao Siffert
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page